Relationship between attentional bias and psychological craving in methamphetamine use disorder

A phase trial for dual-target TMS in methamphetamine addiction puts stimulant-specific neurostimulation on the clinical roadmap for the first time. Here's what the science says about why targeting the brain directly might work when nothing else has.

There's no FDA-approved medication for methamphetamine addiction. A dual-target TMS trial enrolling in 2026 targets the MPFC and DPFC simultaneously — the two brain regions most compromised by chronic stimulant use. Here's the science behind the approach.